AI May Drive Detroit's Next Profit Engine

For decades, this company made its money selling vehicles.

Now it is betting that software and AI could become one of its most powerful profit engines. Are you buckled up for the ride? Read on for all the details.

Insider Strategy (Sponsored)

SpaceX IPO Could Reward Early Investors

For decades, Wall Street insiders have secured the biggest IPO gains before the public ever gets a shot.

Now, one economist says everyday investors may have a rare window to position ahead of a potential $1.5 trillion SpaceX offering.

See how this strategy works by clicking here - and what you should know before the next major IPO announcement.

Capital Strategy

Salesforce Is About to Borrow Up to $25 Billion in a Single Move

Salesforce Inc (NYSE: CRM) is preparing to raise up to $25 billion through a bond sale that could happen as early as this week.

If completed, it would be the single largest debt offering in the company's history.

The money is tied to funding a massive share buyback program the company recently announced.

Borrowing to Buy Back

Most tech giants raising huge debt right now are doing it to fund AI infrastructure. Salesforce is going in a completely different direction.

The company believes its own shares are worth buying at scale, and it is willing to take on historic levels of debt to do it.

You think about what that signals internally. A company does not borrow $25 billion to buy its own shares unless leadership is deeply confident the business is undervalued.

A Different Kind of Bet

While every other tech giant borrows for data centers and chips, Salesforce borrows for itself. That confidence is either perfectly timed or dangerously aggressive.

You will know the answer soon enough. But a company willing to put $25 billion behind its own conviction is making a statement that is impossible to ignore.

CRM currently trades at $194 and pays a dividend of $1.76 per share, a yield of 0.90%.

Pharmaceuticals

The Weight Loss Race Has a New Contender, and It Is Not Who You Expected

AbbVie Inc (NYSE: ABBV) just released the first clinical data from its obesity drug program, showing nearly 10% weight loss in patients after just 12 weeks of treatment.

The drug takes a different approach than the blockbuster GLP-1 treatments already on the market, using a newer class of therapy that may cause fewer side effects.

AbbVie paid $350 million to acquire this drug last year. The early data suggest that investment is starting to look justified.

A Different Path Into the Same Race

The current obesity drug leaders built their dominance on GLP-1 technology. AbbVie is pursuing a different biological target called amylin.

The appeal is that amylin-based drugs may deliver meaningful weight loss with better tolerability, meaning fewer of the stomach-related side effects that cause some patients to quit GLP-1 treatments.

You think about the millions of patients who tried existing weight loss drugs and stopped because of side effects, and a gentler alternative with real results starts to look very valuable.

The Market Is Big Enough for More Players

Obesity treatment is projected to become one of the largest drug categories in history. Demand far exceeds the current supply, and patients want options.

You can see exactly why AbbVie spent $350 million to get into this race early. Even a slice of this market would be transformative for the company.

ABBV currently trades at $229 and pays a dividend of $6.92 per share, a yield of 3.02%.

Gold Strategy (Sponsored)

Protect Your Money From Hidden Rules

Most Americans believe the money in their bank account is unquestionably theirs.

But in a recent federal court proceeding, government attorneys advanced a legal argument that challenges how ownership inside the banking system actually works.

It didn’t make headlines. But the implication is real.

Money held inside banks, brokerage accounts, and retirement plans may be subject to rules most people never examine.

A former precious metals strategist just released a report outlining 3 strategies investors are using to reduce that exposure.

See the full briefing here.

P.S. The guide also explains why IRS-approved physical gold inside certain retirement structures is treated differently from cash-based holdings. If protecting long-term purchasing power and reducing systemic exposure matters to you, review the briefing while it’s still available.

Consumer Goods

Is This the Biggest Reset PepsiCo Has Made in a Generation?

PepsiCo Inc (NASDAQ: PEP) is pulling nearly 20% of its U.S. products from shelves by early 2026 and cutting food prices across the board.

The company is also closing plants, shutting down manufacturing lines, and reducing its workforce to fund the transition.

This is not a seasonal adjustment. This is PepsiCo admitting the old strategy stopped working and taking dramatic action.

Fewer products, lower prices, and a leaner operation. That is the new playbook.

Too Many Products, Too High Prices

PepsiCo pushed prices aggressively over the past few years, and consumers pushed back.

Sales slowed, market share slipped, and shoppers started choosing cheaper alternatives. The product lineup had also grown bloated with items that were not pulling their weight.

You think about walking down a grocery aisle and seeing a dozen versions of the same snack. PepsiCo looked at that same shelf and decided one-fifth of it needs to go.

Rebuilding Around What Sells

PepsiCo is not shrinking. It is refocusing.

The products that survive the cut will get more investment, better pricing, and stronger marketing support. The savings from closures and layoffs fund the pivot.

You can see a company that spent years expanding its lineup and raising prices now reversing both strategies at once.

Whether that reset comes fast enough to win consumers back is the only question that matters now.

PEP currently trades at $159.00 and pays a dividend of $5.69 per share, a yield of 3.57%.

WH has boosted its dividend to 43 cents, a growth of 4.88%. Its new yield is 2.33%.

SCVL has increased its dividend to 17 cents, an increase of 13.33%. Its new yield is 3.6%. 

KFY has raised its dividend to 55 cents, a boost of 14.58%. Its new yield is 3.55%.

JD has increased its dividend to $1.00, a 31.58% increase. Its new yield is 3.96%.

CNQ has raised its dividend to 62 cents, up 6.38%. Its new yield is 5.57%.

TY has dropped its dividend to 28 cents, a reduction of 87.70%. Its new yield is 3.51%. 

Rare Opportunity (Sponsored)

Once-Elite Investment Now Open

For decades, one type of investment was reserved for the ultra-wealthy.

Then Trump signed Executive Order 14330 - and opened it to everyone.

Now you can get into this boom for less than $20.

See what changed

Everything Else

• JPMorgan Chase is scaling back some lending, with the bank reportedly pre-emptively stepping back from private credit loans to software businesses. 

• Google is pushing deeper into Washington with a new tool that enables more than 3 million Pentagon workers to build AI agents for unclassified work tasks.

• CVS brand Aetna will pay $117.7 million to avoid legal action stemming from allegations that it violated the False Claims Act.

• Papa John's is attracting fresh investor attention, with a Qatari-backed fund reportedly lining up a takeover bid.